NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma
Multiple Myeloma, Version 2.2016
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Multiple Myeloma, Version 1.2013
Epidemiology and Outcomes of Clostridium difficile Infections in Hematopoietic Stem Cell Transplant Recipients